Report
EUR 14.08 For Business Accounts Only

ABIOMED sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ABIOMED (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 14, 2022, the closing price was USD 301.22 and its target price was estimated at USD 278.14.
Underlying
ABIOMED Inc.

ABIOMED is a provider of temporary mechanical circulatory support devices, and it provides a continuum of care to heart failure patients. The company's products include: Impella 2.5?, which is a percutaneous micro heart pump with an integrated motor and sensors; which is primarily used by either interventional cardiologists to support patients in the cath lab or by cardiac surgeons in the heart surgery suite; Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, which is a percutaneous catheter-based axial flow pump that is designed to allow more than four liters of flow per minute.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch